Convergences in course of illness and treatments of the epilepsies and recurrent affective disorders.
The failure to achieve and maintain remission is a critical problem for a high percentage of patients with epilepsy and the primary affective disorders. Early illness onset and delayed initiation of treatment may contribute to primary treatment resistance or that associated with loss of efficacy (tolerance phenomenon). Neurobiological data and principles drawn from the amygdala kinding model of seizure progression are reviewed for their heuristic value in conceptualizing molecular mechanisms of illness progression and its prevention with pharmacological agents in the epilepsies and, indirectly, the recurrent affective disorders. Caveats in the use of this model and convergences and divergences in its predictive validity for seizures and affective disorders are noted.
Post
Robert M
RM
Biological Psychiatry Branch, NIMH, NIH, DHHS, Bethesda, MD, USA. Robert.Post@NIH.gov
Weiss
Susan R B
SR
D000679:Amygdala / Q000187:drug effects / Q000503:physiopathology; D000818:Animals; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology; D015897:Comorbidity; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D004569:Electroencephalography / Q000187:drug effects; D017029:Epilepsy, Complex Partial / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D006801:Humans; D007696:Kindling, Neurologic / Q000187:drug effects / Q000502:physiology; D019964:Mood Disorders / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D051381:Rats; D012008:Recurrence; D016896:Treatment Outcome
D000927:Anticonvulsants; D000928:Antidepressive Agents